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Targeted therapies require cellular protein expression that meets speciﬁc requirements
that will maximize effectiveness, minimize off-target toxicities, and provide an opportu-
nity for a therapeutic effect.The receptor tyrosine kinase-like orphan receptors (ROR) are
possible targets for therapy that may meet such requirements. RORs are transmembrane
proteins that are part of the receptor tyrosine kinase (RTK) family. The RORs have been
shown to play a role in tumor-like behavior, such as cell migration and cell invasiveness
and are normally not expressed in normal adult tissue. As part of the large effort in target
discovery, ROR proteins have recently been found to be expressed in human cancers.Their
unique expression proﬁles may provide a novel class of therapeutic targets for small mol-
ecules against the kinase or for antibody-based therapies against these receptors. Being
restricted on tumor cells and not on most normal tissues, RORs are excellent targets for
the treatment of minimal residual disease, the ﬁnal hurdle in the curative approach to many
cancers, including solid tumors such as neuroblastoma. In this review, we summarize the
biology of RORs as they relate to human cancer, and highlight the therapeutic approaches
directed toward them.
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INTRODUCTION
The receptor tyrosine kinase-like orphan receptors (ROR) are
transmembrane proteins that are part of the receptor tyro-
sine kinase (RTK) family. They are related to the Trk–RTK,
muscle-speciﬁc kinase (MuSK), and neurotrophic tyrosine kinase
(NTRTK) receptor families (Masiakowski and Carroll, 1992; For-
rester et al., 1999). The ROR1 and ROR2 genes, ﬁrst identiﬁed
in a neuroblastoma cell line, are located on chromosomes 1 and
9, respectively, both encoding a 104-kDa proteins (Reddy et al.,
1997). Homozygous mutations in ROR2 have been shown to be
responsible for the Robinow syndrome, a skeletal dysplasia syn-
drome characterized by generalized limb shortening, segmental
defects of the spine, and dysmorphic facial appearance, while
heterozygous mutations have been found in patients with dom-
inant brachydactyly B1, characterized by terminal deﬁciency of
ﬁngers and toes (Afzal et al., 2000; Afzal and Jeffery, 2003). The
RORs are made up of an extracellular domain consisting of
an immunoglobulin-like motif, a cysteine-rich frizzled domain,
a kringle domain, and an intracellular tyrosine kinase domain
(Figure 1). They were named orphan receptors because their
endogenous ligands had not yet been discovered. However,recent
studies have shown that the frizzle-domain of ROR2 associates
with the Wnt5a protein and is involved with the non-canonical
Wnt pathways (McDonald and Silver, 2009), but the deﬁnitive
ligand for ROR1 is yet to be determined. The RORs have been
shown to play a role in establishing cellular polarity (Green et al.,
2008) and in tumor-like behavior, such as cell migration and cell
invasiveness (Morioka et al., 2009). These receptors are normally
expressed at high levels during development, playing a key role in
skeletal and neural organogenesis, but then become repressed in
adulttissues(Al-Shawietal.,2001).Interestingly,ROR1isupregu-
latedinB-cellchroniclymphocyticleukemia(B-CLL;Baskaretal.,
2008), B-cell acute lymphocytic leukemia (B-ALL; Shabani et al.,
2008),andmantlecellleukemia(MCL;Hudeceketal.,2010),while
ROR2isoverexpressedinosteosarcoma(OS;Moriokaetal.,2009),
and renal cell carcinoma (RCC; Wright et al., 2009). This unique
expressionproﬁlemayprovideanovelfamilyoftherapeutictargets
for small molecules against the kinase or for antibody-based ther-
apies against these receptors (Hudecek et al.,2010). In this review,
wesummarizethebiologyof RORsastheyrelatetohumancancer,
and highlight the therapeutic approaches directed toward them.
RECEPTOR PROPERTIES OF ROR PROTEINS
Receptor tyrosine kinase-like orphan receptors are membrane
proteins composed of three extracellular domains, one trans-
membrane domain, and one intracellular domain. Comparative
genomic studies have found that the three extracellular domains
and the one intracellular domain are conserved from drosophila
and Caenorhabditis elegans to mice to humans (Figure 1; Katoh,
2005).TwodifferentsplicevariantshavebeenidentiﬁedforROR1,
one lacking all the extracellular domains known as truncated-
ROR1(t-ROR1)andonelackingboththeintracellulardomainand
transmembrane domains (Reddy et al.,1996). So far most studies
have focused on the full length form of ROR1. Some reports have
claimedthattheintracellulartyrosinekinasedomainlacksbiolog-
ical activity (Gentile et al., 2011), while others suggest its critical
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FIGURE 1 | Structure of receptor tyrosine kinase-like orphan receptor
(ROR) in different species.Type 1 receptor tyrosine kinase evolutionarily
conserved, co-receptor with Frizzled-2/4, with immunoglobulin (Ig) domain,
cysteine-rich domain (CRD), and Kringle domain.The intracellular portion
contains tyrosine kinase (TK) domain, proline-rich domain (PRD) ﬂanked by
Ser/Thr rich domains (S/TRD1 and 2; Green et al., 2008; Minami et al., 2010).
role in signal transduction to downstream proteins (Mikels et al.,
2009). The kinase activity of ROR2, on the other hand, has been
well-established(Kanietal.,2004;Yamamotoetal.,2007;Liuetal.,
2008). We will discuss ROR2 kinase activity in more details later.
Intriguingly, vertebrate ROR proteins seem to have acquired
additionalcytosolicdomainsimportantfordownstreamsignaling.
Inadditiontothetyrosinekinasedomain,vertebrateRORscontain
a serine/threonine-rich domain (S/TRD1), a proline-rich domain
(PRD),andanadditionalserine/threonine-richdomain(S/TRD2;
Minami et al., 2010). Current studies have mainly focused on
the extracellular cysteine-rich domain (CRD) in Frizzle since this
domain has been shown to bind Wnt ligands for other cell sur-
face receptors (Rehn et al., 1998). Studies in drosophila and mice
have identiﬁed Wnt5a to be a ligand for ROR2 by comparing
expression levels and loss-of-function phenotypes between ROR2
and Wnt5a homologs (Oishi et al., 2003; Green et al., 2007). Co-
expression and co-immunoprecipitation studies have shown that
Wnt5b could also bind to ROR2 in osteosarcoma cells (Morioka
et al., 2009). Yet, the deﬁnitive ligand for ROR1 is still uncertain.
The properties of the immunoglobulin domain and kringle extra-
cellulardomainshavenotbeenwellcharacterized;thus,theunder-
standing of the key biologic function of ROR proteins remains
incomplete.
Mikels et al. (2009) has shown that ROR2 and its ligand,
Wnt5a might be involved in the non-canonical Wnt pathway.
In vivo studies in mice have shown that when mROR2 or Wnt5a
expressionisknockeddown,Wnt/β-cateninsignalingisenhanced,
consistent with ROR2’s function as an inhibitor of canonical Wnt
pathways. Furthermore, the CRD, immunoglobulin-like extracel-
lular domains, and intracellular tyrosine kinase domain all seem
necessary for inhibition to occur, since truncated forms of ROR2
losetheirinhibitoryfunction.Thecanonicalpathwaycouldalsobe
inhibited through theWnt/calcium pathway via CamKII (Ishitani
etal.,2003).WhenWnt5abindstoROR2,CamKIIisactivated,and
through the mitogen-activated protein kinase (MAPK) pathway,
negatively regulates the canonical Wnt/β-catenin signaling. These
inhibitory pathways against canonical signaling may function as
fail-safes to prevent aberrant β-catenin-induced gene expression
from cancer-promoting activity. This tumor-suppressing effect
has been proposed for high risk neuroblastoma since Wnt5a is
down-regulated in neuroblastoma cell lines (Blanc et al.,2005).
EXPRESSION PATTERN DURING NORMAL DEVELOPMENT
Receptor tyrosine kinase-like orphan receptors play a signiﬁ-
cant role in embryonic development. Studies of ROR orthologs
found in C. elegans, Drosophila melanogaster, Xenopus, and mice
have mapped the expression proﬁles of RORs during develop-
ment demonstrating a striking conservation during evolution to
human (Wilson et al., 1993; Yoda et al., 2003). When the C. ele-
gans ROR ortholog, CAM-1, was mutated, normal migration of
canal-associated neurons was disrupted, suggesting a critical role
of RORs in neuronal development. In mice, mRor1 and mRor2
are highly expressed during the early stages of development, rep-
resented in most of the major systems in tissues derived from
all three germ layers, but most prominently seen in neural crest
cells and their derivatives, such as special sense organs (Al-Shawi
et al., 2001). While mRor2 is broadly expressed in the developing
nervous system, mRor1 is restricted primarily to the head mes-
enchyme during fetal development (Oishi et al., 1999; Al-Shawi
et al., 2001). In earlier report, knockout phenotype could not
be studied since mRor1−/− m i c ed on o ts u r v i v eb e y o n d2 4ho f
life, dying from respiratory dysfunction, highly suggestive of the
role of ROR1 in normal lung development (Al-Shawi et al., 2001;
Nomi et al.,2001). A recent study showed that ROR1−/− mutants
couldsurvive,butwithgrowthretardation.Thesemutantmicehad
multipleskeletaldefectsandurogenitalabnormalities,resultingin
reduced life expectancy and female infertility (Lyashenko et al.,
2010). Ror2-deﬁcient mice are viable,but have well-deﬁned skele-
tal and heart abnormalities, modulated to some extent by mRor1
(Nomi et al., 2001). Although RORs are critical during normal
development, they become undetectable in normal adult tissues,
including humans. ROR1 is not expressed in mature B-cells, T-
cells, monocytes, and natural killer cells; but transient expression
was found at intermediate stage of normal B-cell development
and the earliest B-cell precursors in the bone marrow. ROR1 was
expressed in undifferentiated ES cells and expression was down-
regulated upon differentiation in conditioned medium (Hudecek
et al.,2010).
ABERRANT EXPRESSION OF RORs IN CANCER
Although expression of RORs is embryonal,limited to the normal
stagesof development,theiraberrantexpressionincertaincancers
is of interest. As an oncofetal antigen,high levels of ROR1 expres-
sion have been found as mRNA and as protein in B-CLL (Baskar
et al.,2008; Daneshmanesh et al.,2008; Fukuda et al.,2008),while
totallyabsentinhealthydonorperipheralbloodmononuclearcells
(PBMC) and all other normal tissues except for tonsillar B-cells
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(Daneshmaneshetal.,2008).ROR1ispreferentiallyexpressedover
ROR2 in B-CLL cells. Furthermore, it is constitutively expressed
on B-CLL cells despite B-cell activation via CD40L and IL-4. The
pattern of expression did not differ between IgVH mutated and
unmutated B-CLL cases (Daneshmanesh et al.,2008). In addition
toB-CLL,ROR1wasalsoupregulatedatthemRNAlevelinB-ALL
(Shabani et al., 2008). ROR1 was only overexpressed in mature
leukemicB-cellsbutnotinimmatureforms(Shabanietal.,2008).
IL-6couldregulateROR1expressionthroughStat3inCLLcells(Li
etal.,2010).ROR1wasextensivelymodiﬁedbyN-linkedglycosyla-
tion(Kauckaetal.,2011),producingvariantswithelectrophoretic
migration of approximately 100, 115, and 130kDa. Inhibition of
glycosylation interfered with cell surface localization of the 130-
kDa variant of ROR1 and prevented Ror1-induced formation of
ﬁlopodia.The130-kDaformwasmono-ubiquitinated.Duetovar-
ious glycosylation patterns, ROR1 from individual CLL patients
showed striking differences in the electrophoretic mobility.
Amongsolidtumors,ROR1hadincreasedexpressioningastric
carcinoma and non-small cell carcinoma cell lines (Gentile et al.,
2011). Here ROR1 functions as a pseudokinase crucial for Met-
driven tumorigenesis. On the other hand, ROR2 was upregulated
in osteosarcoma and RCC cell lines, as well as primary tumors,
while not on normal tissues except for thyroid and stomach
(Morioka et al.,2009;Wright et al.,2009). In sum,this differential
expression of RORs among human cancers and the low to absent
expressioninnormaltissuessupporttheirpotentialastherapeutic
targets both in leukemia and in select solid tumors. In neuroblas-
toma,ROR1andROR2wereexpressedinalltumorstages.Among
patients,high levels of ROR1 or ROR2 gene expression correlated
signiﬁcantly with poorer survival (Asgharzadeh et al., 2006).
ONCOGENIC PROPERTIES OF RORs
Although in neuroblastoma, Wnt5a/ROR signaling was hypoth-
esized to have tumor-suppressing effects, several studies using
other human cancers have shown the complete opposite,in which
Wnt/ROR signaling induces tumor proliferation and tumor inva-
siveness. The ROR2/Wnt5a pathway has been shown to involve
signaling through Wnt-c-Jun N-terminal kinase (Jnk) via acti-
vation of the actin binding protein, ﬁlamin A, which binds to
the PRD intracellular domain in vertebrates (Oishi et al., 2003;
Nomachi et al., 2008). Through activation of this pathway, mice
ﬁbroblasts could be induced to undergo cellular migration and
invasion, features pathognomonic of malignancy. siRNA studies
of osteosarcoma cells have shown a strong correlation between
ROR2knockdownanddecreasedcellmigrationintranswellassays
(Enomoto et al., 2009). Furthermore, introduction of ROR2 into
human ﬁbroblast and kidney cells greatly enhanced the invasive
activityof thesecells.WhenknockeddownbysiRNA,theviability
and survival of these cells decreased (Morioka et al., 2009). This
effect of gene knockdown was also seen in RCC cells, where the
suppressionof ROR2expressionnotonlydecreasedthemigration
of RCC cells, but also inhibited anchorage-independent growth
in soft agar and growth in an orthotopic xenograft mouse model
(Wright et al., 2009). Furthermore, ROR2 knockdown by siRNA
inhibited invasion of melanoma cells in a murine in vivo tumor
model(O’Connelletal.,2010).AllthesestudiesimpliesROR2role
in tumorigenesis and progression.
ROR1 was reported to be upregulated in B-CLL. Studies con-
ducted by Choudhury et al. (2010) showed that silencing of
ROR1 with siRNA results in apoptosis of primary B-CLL cells
from patients, but not PBMC from healthy donors. It was found
that ROR1 is constitutively phosphorylated in the B-CLL cells of
al patients tested. Using a siRNA screening method, ROR1 was
identiﬁed as a key factor for survival of t(1:19) acute lymphoblas-
tic leukemia (ALL) primary cells and cell lines in vitro (Bicocca
et al., 2011). Interestingly, ROR1 was elevated only in the t(1:19)
ALL and not other ALL subtypes. It remains to be investigated
whether ROR1 is phosphorylated in t(1:19) ALL cells. In a trans-
genic mice model, studies suggested that ROR1 can accelerate the
development of CLL. In these studies, transgenic mice express-
ing human ROR1 under control of a B-cell speciﬁc promoter
developed hROR1+/CD5+/B220 low B-cell leukemia resembling
human CLL at 15–18months of age. These human ROR1 trans-
genicmicewerefurthercrossedwithTCL1transgenicmice,which
at 7months of age develop CD5+B220 low leukemia B-cells.
The F1 mice with both transgenes (hROR1×TCL1) developed
hROR1+/CD5+/B220 low leukemia B-cell CLL at a signiﬁcantly
youngermedianagethandidlittermate-controlmicehavingeither
transgene alone (Cui et al., 2011).
To further explore the invasive character of these cells upon
ROR activation, invadopodia, and extracellular matrix (ECM)
remodeling proteins, such as matrix metalloproteinases (MMPs),
were studied to see if these components were co-expressed with
ROR. In order for cells to migrate, the ECM has to be remodeled
to allow for the cell to migrate through the extracellular milieu.
Invadopodia are actin-rich protrusions that degrade and extend
into the ECM, remodeling the ECM for tumor migration and
invasion (Bowden et al., 1999), while MMPs are enzymes that
degrade collagen and other components of the ECM. Through
immunostaining and ECM degrading assays, ROR2 was seen to
be concentrated in regions where invadopodia were located, as
determined by the location of cortactin, an essential component
of invadopodia that is expressed in areas where the ECM has
beendegraded(Enomotoetal.,2009).Furthermore,acomparison
betweenseveralMMPsandROR2expressioninosteosarcomacells
was studied and found that when ROR2 was silenced via transfec-
tion of siROR2, MMP13, a collagenase, was also decreased. The
same effect was seen when siWnt5a was introduced into OS cells,
suggesting that MMP13 is activated through Wnt5a/ROR2 sig-
naling (Enomoto et al., 2009; Minami et al., 2010). Staining of
invadopodia for MMP13 also indicated its presence in this ECM
remodelingcomplex.Closeranalysisofthesignalingpathwayindi-
cated that the tyrosine kinase domain of ROR2 was essential for
MMP13activationandsubsequentECMremodelingandthatSrc-
familyproteintyrosinekinases(SFKs),aseriesof kinasesshownto
play an essential role in invadopodia production (Weaver, 2006),
were shown to be activated through Wnt5a/ROR2 signaling. This
then suggested that Wnt5a/ROR2 signaling activated a SFK, lead-
ing to subsequent activation of MMP13, overall leading to ECM
remodeling to allow for tumor migration and invasion. A sim-
ilar ﬁnding was found in RCC cells, in which ROR2 regulated
MMP2, shown to be overexpressed in many metastatic cancers
(Kurban et al., 2006) and play a important role in the renal tubu-
lar cell epithelial to mesenchymal transformation during wound
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healing, leading to ECM remodeling and subsequent invasive
growth (Wright et al.,2009).
THERAPEUTIC APPROACH AGAINST ROR
SMALL MOLECULE INHIBITORS
Giventheirrestrictedtissuedistributionandimplicationincancer,
RORs are potential targets for cancer therapy (see Table 1). The
TK domain of RORs is homologous to the discoidin-like domain
receptor(Ddr),muscle-speciﬁckinase(MuSK),andmostof all,to
the tropomyosin receptor kinase (Trk) family of receptors (Masi-
akowski and Carroll, 1992; Green et al., 2008). These receptors
recognize the Src homology domain 2 (SH2) on phosphotyro-
sine substrates that constitute phosphorylation sites that lead to
downstream transduction of the signal (Sadowski et al., 1986).
Furthermore,SH3 substrates recognize PRDs,which are found in
vertebrate ROR proteins. Since these domains are very speciﬁc for
interaction with the phosphorylated portions of the TK domain,
blockingtheiractivitycouldbeaneffectivewaytotruncatethesig-
nal transduction responsible for oncogenesis (Vidal et al., 2001).
However, recent work (Gentile et al.,2011) on the tyrosine kinase
domain of ROR1 showed that ROR1 is a pseudokinase. Overex-
pressionofROR1failedtoleadtokinaseautophosphorylation,nor
was it able to phosphorylate exogenous substrates. Moreover, the
intracellular kinase domain of ROR1 contains amino acid substi-
tutionsinpositionsknowntobecriticalfortheenzymaticfunction
of tyrosine kinase. On the contrary, constitutively activated MET
receptor tyrosine kinase leads to ROR1 phosphorylation in gas-
tric carcinoma cells (HS746T) and non-small cell lung carcinoma
cells (NCI-H1993). Knockdown of ROR1 by siRNA in these two
cell lines induces apoptosis in vitro and inhibits tumor growth in
mousetumormodels.Noticeably,ROR1knockdownhasnoeffect
on cell survival in cancer cells where ROR1 is overexpressed but
not phosphorylated.
It was reported that in t(1:19)ALL cells,combination of ROR1
knockdown and a kinase inhibitor, dasatinib, resulted in additive
impairmentofcellviabilitycomparedwithdasatinibalone,imply-
ing that therapies blocking ROR1 function might sensitize cancer
cells to small molecule kinase inhibitors. Dasatinib was known to
inhibit the kinase activities of Bruton’s tyrosine kinase (BTK) and
tyrosine-protein kinase Lyn, which in turn leads to downregulat-
ing activity of AKT. In support of the hypothesis that ROR1 also
serve to regulate AKT activity, ROR1 knockdown results in AKT
inhibition in t(1:19) ALL cells (Bicocca et al., 2011).
The kinase activity of ROR2 is better understood. Using
HEK293 transient expression system as a model system, Kani et
al. has shown that ROR2 is phosphorylated by casein kinase Iε,a
crucial regulator of the canonical Wnt signaling. Casein kinase Iε
phosphorylatesROR2onserine/threonineresidues,whichinturn
resulted in autophosphorylation of ROR2 on tyrosine residues.
Moreover, phosphorylated ROR2 might further phosphorylate G
protein-coupled receptor kinase 2 (Kani et al., 2004). It was later
shown in NIH3T3 and HeLa-S3 cells that simulation with Wnt5a
results in ROR2 phosphorylation on serine/threonine residues.
And this phosphorylation is mediated by GSK-3α (and GSK-3β;
Yamamoto et al., 2007). Interestingly, Liu et al. (2008) found
in human U2OS osteosarcoma cells that Wnt5a was able to
induce homodimerization of ROR2 and autophosphorylation of
its tyrosine residues without phosphorylation of serine/threonine
residues. However, despite the strong evidence of ROR2 involve-
mentintumorigenesisandprogress,therearenopublishedreports
on small molecule inhibitors against ROR2.
ANTIBODY-BASED TARGETED THERAPY
As surface receptors, RORs are potential targets for monoclonal
antibodies (MoAb). Among non-hematopoietic tissues, only adi-
pose tissue express cell surface ROR1 (Baskar et al., 2008). The
Table 1 | Summary of evidence for human ROR1/2 as cancer therapeutic targets.
Properties Human ROR1 Human ROR2 Reference
Expression in adult tissues Adipose tissuea Thyroid and stomachb Baskar et al. (2008), Morioka et al. (2009)
Genetic diseases linked to gene
mutation
ND Brachydactyly type B and
Robinow syndrome
Schwabe et al. (2000), van Bokhoven et al. (2000)
Ligand ND Wnt5a Liu et al. (2008), Maeda et al. (2012)
Tyrosine kinase activity Pseudokinase Yes Gentile et al. (2011), Liu et al. (2008), Kani et al.
(2004),Yamamoto et al. (2007)
Cancer types with ROR
overexpression
B-CLL, ALL,
neuroblastoma, breast
cancer, renal cancer
Osteosarcoma, melanoma,
renal cell carcinoma,
leiomyosarcoma,
gastrointestinal stromal
tumor, and oral cancer
Baskar et al. (2008), Shabani et al. (2008),
Asgharzadeh et al. (2006), Zhang et al. (2012),
Rabbani et al. (2010), Morioka et al. (2009),
O’Connell et al. (2010),Wright et al. (2009), Edris
et al. (2012), Kobayashi et al. (2009)
Inhibition of cancer cell
proliferation/invasion by siRNA
Yes Yes Choudhury et al. (2010), Wright et al. (2009),
O’Connell et al. (2010)
In vivo inhibition of tumor
growth/invasion by siRNA/mAb
Yes Yes Cui et al. (2011), Gentile et al. (2011), Zhang et al.
(2012),Wright et al. (2009), O’Connell et al. (2010)
aProtein expression examined by Western blot. Cell surface ROR1 only. It remains possible that cell surface ROR1 is expressed at very low levels in testis, uterus,
lung, bladder, and colon.
bmRNA expression examined by Northern blot. Very weak expression signals were detected in thyroid and stomach.
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restricted pattern of expression among normal tissues makes
ROR1 an attractive target for MoAbs. High afﬁnity MoAb have
been derived from a chimeric rabbit/human Fab library and
applied to the CLL and MCL lymphoma preclinical models (Yang
et al., 2011). These antibodies have rabbit variable domains and
human constant domains. Afﬁnities of the Fab by BIACORE
ranged from 0.56 to 8.8nM. As full IgG1, the virtual afﬁnities
were0.04–0.7nM.Antibodieswiththehighestafﬁnityandslowest
rate of internalization could mediate antibody-dependent cell-
mediated cytotoxicity (ADCC), but not complement mediated
cytotoxicity (CDC). Using lymphoma cell line as target, ADCC
was observed only for the high afﬁnity antibody at 5μg/ml, sub-
stantially weaker than anti-CD20 antibody rituximab. Antibody
internalization appeared slower with the high afﬁnity antibody.
None of the antibodies induced apoptosis in lymphoma cells. The
advantageoftheseantibodiescomparedtoothertherapeuticB-cell
speciﬁc MoAbs is the absence of ROR1 in mature B-cells (Hude-
cek et al., 2010). However, given the relatively low cell surface
density,ROR1wasproposedasapreferredtargetforarmedrather
thannakedMoAb(Yangetal.,2011).SinceROR1mediatespartial
internalization of bound antibody by endocytosis,it also provides
a means to deliver cytotoxic agents into tumor cells (Baskar et al.,
2008).
Other efforts, however, identiﬁed ROR1 MoAbs that are cyto-
toxic to hROR1-expressing leukemia cells (Cui et al., 2011;
Daneshmanesh et al., 2012). In one study, over 70 unique
mAbs against human ROR1 extracellular domain were generated
through immunizing mice with various formats of full length
hROR1–ECD peptides. Most mAbs recognize epitopes within the
ROR1Ig-likedomain;othersrecognizeepitopeswithinthekringle
domain. One mAb binds to a unique epitope between the Ig
and CRD domain, and is directly cytotoxic to hROR1-expressing
leukemia cells in vitro. This mAb can also signiﬁcantly decrease
the basal levels of phosphorylated AKT in primary CLL cells and
hROR1-expressing leukemic cells. Moreover, treatment of this
mAb signiﬁcantly decreased the number of primary CLL cells
transferred into the peritoneal cavity of NSG mice, and inhibited
CLL cell engraftment in the hROR1×TCL1 double transgenic
adoptivetransfermodelmentionedpreviouslyinthereview.CDC
activity against primary CLL cells and hROR1-expressing can-
cer cell lines was also observed for this mAb. In the other study,
Mellstedt’lab has generated ﬁve mouse by immunizing 15- to 23-
amino-acid-long peptides derived from Ig domain,CRD domain,
and kringle domain of human ROR1. All the ﬁve mAbs induce
apoptosis of primary B-CLL cells but not of normal B-cells. Most
effectiveweretwomAbsagainstCRDandkringledomains,respec-
tively.Theyshowedsigniﬁcantsuperioritytorituximab.Twoofthe
mAbs induced CDC similar to that of rituximab, and one mAb
against the kringle domain showed ADCC activity against ROR1-
expressing cancer cells. The discrepancy among the three studies
might be explained by the different binding epitope of unique
hROR1-speciﬁc MoAbs. Table 2 summarizes reported studies of
ROR1 MoAbs.
Another approach to overcome the low receptor density of
ROR1 was to exploit T-cells. By genetic modiﬁcation, T-cells can
be made to express a chimeric antigen receptor (CAR) speciﬁc
for ROR1, retargeting T-cell-mediated cytotoxicity against tumor
cells (Hudecek et al., 2010). Since these CD8+ modiﬁed T-cells
are efﬁcient killers, probably requiring few target antigens, and
no longer restricted to HLA or HLA type, this approach can
potentially tackle three signiﬁcant issues simultaneously, i.e., low
target density, low HLA expression, and HLA type restriction
of natural T cell epitopes. ROR1–CAR transduced T-cells efﬁ-
ciently lysed primary B-CLL, primary MCL, and ROR1-positive
tumor cell lines including the rare subset of CLL cells that efﬂux
chemotherapy, but not normal resting or activated B-cells. These
T-cells also produced effector cytokines including TNF-α, IFN-
γ, and IL-2, and were capable of proliferating in response to
ROR1-expressing tumor cells (Hudecek et al., 2010). Whether
the T-cells were derived from normal volunteers or from CLL
patients, CAR-modiﬁcation made them equally effective against
ROR1-positive targets. Another obvious alternative may be the
useof bispeciﬁcantibodiessuchasBispeciﬁcT-cellengaginganti-
bodies (BiTE; Bargou et al., 2008; Choi et al., 2011). However, for
Table 2 | Biological activity of ROR1-speciﬁc MoAbs against human primary chronic lymphocytic leukemia (CLL).
Reference Antibody Epitoped Afﬁnity (KD) ADCC CDC Apoptosis Internalization Inhibition of tumor
growth (in vivo)
Daneshmanesh et al. (2012) 3B8 (IgMa) Ig ND ND No Yes ND ND
1C11 (IgMa) CRD ND ND No Yes ND ND
1D8 (IgG1a) CRD ND ND Yes Yes ND ND
4A7 (IgG1a) KNG ND Yes Yes Yes ND ND
4C10 (IgMa) KNG ND ND No Yes ND ND
Yang et al. (2011) R11 (IgG1b) KNG 0.19nM No No No Strong ND
R12 (IgG1b) Ig/CRD 0.11nM Yes No No Modest ND
Y31 (IgG1b) CRD/KNG 0.71nM No No No Strong ND
Cui et al. (2011) UC D10a,c Ig/CRD 41nM ND Yes Yes ND Yes
aMouse antibody.
bRabbit/human chimeric IgG1 antibody.
cTarget cells for biological activity includes ROR1-positive leukemia cell lines, in addition to primary CLL cells.
dRefer to Figure 1 for domain description.
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monovalentconstructs,highafﬁnityROR-speciﬁcantibodiesmay
be needed.
FUTURE DIRECTIONS
As part of the large effort in target discovery, ROR proteins have
recently been characterized as unique markers for several cancers.
Being restricted on tumor cells and not on most normal tissues,
RORs are excellent targets for the treatment of minimal residual
disease,the ﬁnal hurdle in the curative approach to many cancers,
including solid tumors such as neuroblastoma. Currently, ROR1
is used as a diagnostic tool for CLL (Uhrmacher et al., 2011), and
is likely a critical receptor in the evolution of other non-Hodgkin
lymphomas,suchasMCLandmarginalzonelymphoma(Hudecek
et al., 2010; Barna et al., 2011). Most attention has been focused
on ROR1 for targeted measures (Gentile et al., 2011), however
ROR2 remains a viable target candidate. A deeper understand-
ing of the signaling pathway of both ROR1 and ROR2 will go
a long way in designing rational therapy. Clarity on the dual-
ity of Wnt5a signaling as a tumor-suppressor and an oncogenic
protein is needed, with full characterization of the cellular envi-
ronment and conditions that promote either fate. Several reports
point to the receptor proﬁle on the cell surface as a marker to
determine whichWnt signal dictates the cell,showing thatWnt5a
could induce clathrin-mediated internalization when bound to a
Frizzle2-containingreceptor,suppressingtheabilityofWnt3a,also
a putative ligand for ROR2 that leads to canonical β-catenin accu-
mulation, to bind to ROR2. This establishes a dose-dependent
environment for whichever Wnt ligand can ﬁrst bind to ROR2
and dictates the signaling pathway (Liu et al., 2008; Sato et al.,
2010).ThereisfurthersuggestionthatthepresenceoftheFrizzle4-
containing receptor could also bindWnt5a and induce the canon-
ical β-catenin-dependent pathway, suggesting that Wnt signaling
is dictated by receptor availability as opposed to the Wnt ligands
themselves (Mikels and Nusse, 2006). This interesting dichotomy
could provide new insight into the mechanism behind tumor
metastasis and invasion via Wnt/ROR signaling. Another issue
that needs to be further resolved is to determine the number of
RORmoleculespresentonthecellsurfaceinorderforfutureanti-
body therapies to be effective. For efﬁcient antibody-dependent
cell-mediated cytotoxicity (ADCC) and complement dependent
cytotoxicity (CDC), there needs to be enough molecules of the
antigen present on the cell surface to actively engage these cellular
processes. In B-CLL cells and neuroblastoma, the antigen density
was on the lower end around 103–104 molecules per cell, thereby
limiting the capabilities of ADCC and CDC (Baskar et al., 2008;
Yang et al., 2011). On the other hand, the antigen density needed
for NK or T-cell-mediated cytotoxicities could be much less strin-
gent (Tassev et al., 2012). Strategies to increase RORs expression
on tumor cells using cytokines may be a possible solution. Alter-
natively, highly potent toxin immunoconjugates, radioimmuno-
conjugates,bispeciﬁc antibodies,or CAR-retargeted T-cells or NK
cells could overcome these antigen density limitations.
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